A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04380805 |
|
Recruitment Status :
Completed
First Posted : May 8, 2020
Last Update Posted : October 21, 2022
|
Sponsor:
Akeso
Collaborator:
Akesobio Australia Pty Ltd
Information provided by (Responsible Party):
Akeso
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | August 29, 2022 |
| Actual Study Completion Date : | September 15, 2022 |